In this session, Dr Joyce O'Shaughnessy from Texas Oncology discusses strategies for optimizing endocrine therapy for patients with metastatic hormone receptor positive breast cancer.
Joyce Shaughnessy said it is a drag topic… drag to talk about it? Try having it. Then see how much a drag it is. Words matter. Doctors who are so impressed with their knowledge have no flipping clue.
I think she means it is a drag because the disease was not caught before it had spread. That is what we all want. Sadly, not happening for all. I have invasive lobular, about 15% of cases, and it has not been studied as much. The trials tend to focus on the more common invasive ductal. I have not watched all of this yet, but some of it looks good. Some oncologists don't even know as much about these CDK inhibitors. Watch The Cancer Guy with the CTOAM. His specialty is precision medicine. One study showed that there was a difference in using the targeted medicine FIRST--not doing the chemo and older inhibitors first and then bringing in the targeted one. There is even a newer inhibitor available. You can have consultations with CTOAM to get the DNA sequence of the cancer so that you don't have to try medications that don't work. The CTOAM has a woman who is an advocate for targeted medicine, and she works with oncologists to use these targeted medicines. I think this lady knows what she is talking about.
